Elevated prevalence of nodal positivity in carcinoid tumours of the appendix smaller than 2 cm has a negative impact on overall survival

2020 ◽  
Vol 22 (12) ◽  
pp. 1958-1964
Author(s):  
M. Skancke ◽  
S. P. Sharp ◽  
D. J. Maron ◽  
S. D. Wexner
Keyword(s):  
Overall Survival ◽  
Negative Impact ◽  
Carcinoid Tumours

scholarly journals The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients

2020 ◽  
Author(s):  
Alexandre A. Jácome ◽  
Timothy J. Vreeland ◽  
Benny Johnson ◽  
Yoshikuni Kawaguchi ◽  
Steven H. Wei ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Liver Resection ◽  
Age Of Onset ◽  
Negative Impact ◽  
Late Onset ◽  
Linear Regression Analysis ◽  
Multidisciplinary Treatment ◽  
Prognostic Impact ◽  
The Impact

Abstract Background The impact of molecular aberrations on survival after resection of colorectal liver metastases (CLM) in patients with early-age-onset (EOCRC) versus late-age-onset colorectal cancer (LOCRC) is unknown. Methods Patients who underwent liver resection for CLM with known RAS, BRAF and MSI status were retrospectively studied. The prognostic impact of RAS mutations by age was analysed with age as a categorical variable and a continuous variable. Results The study included 573 patients, 192 with EOCRC and 381 with LOCRC. The younger the age of onset of CRC, the greater the negative impact on overall survival of RAS mutations in the LOCRC, EOCRC, and ≤40 years (hazard ratio (HR), 1.64 (95% confidence interval (CI), 1.23–2.20), 2.03 (95% CI, 1.30–3.17), and 2.97 (95% CI, 1.44–6.14), respectively. Age-specific mortality risk and linear regression analysis also demonstrated that RAS mutations had a greater impact on survival in EOCRC than in LOCRC (slope: −4.07, 95% CI −8.10 to 0.04, P = 0.047, R2 = 0.08). Conclusion Among patients undergoing CLM resection, RAS mutations have a greater negative influence on survival in patients with EOCRC, more so in patients ≤40 years, than in patients with LOCRC and should be considered as a prognostic factor in multidisciplinary treatment planning.

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group

Blood ◽  
2009 ◽  
Vol 113 (19) ◽  
pp. 4505-4511 ◽  
Author(s):  
Verena Ingeborg Gaidzik ◽  
Richard Friedrich Schlenk ◽  
Simone Moschny ◽  
Annegret Becker ◽  
Lars Bullinger ◽  
...  
Keyword(s):  
Overall Survival ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Negative Impact ◽  
Serum Lactate Dehydrogenase ◽  
Study Group ◽  
Prognostic Impact ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Acute Myeloid

AbstractTo evaluate the incidence and clinical impact of WT1 gene mutations in younger adult patients with cytogenetically normal acute myeloid leukemia (CN-AML), sequencing of the complete coding region was performed in diagnostic samples from 617 patients who were treated on 3 German-Austrian AML Study Group protocols. WT1 mutations were identified in 78 (12.6%) of the 617 patients; mutations clustered in exon 7 (54 of 78) and exon 9 (13 of 78), but also occurred in exons 1, 2, 3, and 8. WT1 mutations were significantly associated with younger age, higher serum lactate dehydrogenase levels, higher blood blast counts, and the additional presence of FLT3-ITD (P < .001) and CEBPA mutations (P = .004). There was no difference in relapse-free survival and overall survival between patients with (WT1mut) or without WT1 mutations. Subset analysis showed that patients with the genotype WT1mut/FLT3-ITDpos had a lower complete remission rate (P = .003) and an inferior relapse-free survival (P = .006) and overall survival (P < .001) compared with those with the genotype WT1mut/FLT3-ITDneg. In conclusion, in our large cohort of younger adults with CN-AML, WT1 mutation as a single molecular marker did not impact on outcome. However, our data suggest a negative impact of the genotype WT1mut/FLT3-ITDpos.

Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2865-2865 ◽  
Author(s):  
Louise De Swart ◽  
Chloé Reiniers ◽  
Tim Bagguley ◽  
David Bowen ◽  
Jaroslav Cermak ◽  
...  
Keyword(s):  
Overall Survival ◽  
Iron Overload ◽  
Lower Risk ◽  
Negative Impact ◽  
Cumulative Number ◽  
Iron Species ◽  
Cox Regression Analysis ◽  
Landmark Analysis ◽  
Plasma Iron

Abstract Background: The EUMDS registry collects prospective observational data on lower-risk MDS patients from 142 centers in 17 countries. Red blood cell (RBC) transfusions remain one of the cornerstones in supportive care. Patients are prone to iron overload due to long-term iron accumulation either caused by RBC transfusions or ineffective erythropoiesis and associated iron toxicity through the formation of toxic iron species. Methods: We analyzed serum from 100 lower-risk MDS patients at six-month intervals for ferritin, transferrin saturation (TSAT), hepcidin-25, and toxic iron species (non-transferrin bound iron (NTBI) and labile plasma iron (LPI)) in order to evaluate temporal changes in iron metabolism and presence of potentially toxic forms of ironand their impact on survival. Results: Themedian age was 73 years (range 44-95 years). WHO2001 MDS-subtypes were RCMD (37%), RARS (30%), RA (18%), RAEB (7%), 5q-syndrome (4%) and RCMD-RS (4%). The table shows iron parameters at registration, 1 and 2 years follow-up both in transfusion-dependent (TD) and transfusion-independent (TI) patients and according to: MDS-RS (RARS/RCMD-RS) or MDS Other (RA/RCMD/RAEB/5q-syndrome). Serum ferritin levelswere increased in TD patients, compared to TI patients. Ferritin correlated significantly with hepcidin-25 (r=0.57, p<0.001) as well as CRP (r=0.27, p<0.001). Hepcidin-25 levelswere elevated in TD patients at registration and remained elevated during follow-up (Table 1). Hepcidin levels were low in MDS-RS TI patients at all time points compared to nonRS MDS patients (Table 1). NTBI levelswere elevated in TD patients compared to TI patients at registration and during follow-up. Also TI MDS-RS patients had NTBI levels above the lower limit of detection (LLOD; 0.47 µmol/L). NTBI levels over time were highest in TD MDS-RS patients. LPI levelswere mainly increased above LLOD (0.21 µmol/L) in patients with high TSAT levels (>80%). Both NTBI and LPI had a stronger association with TSAT (Figure 1AC) compared to ferritin (Figure 1BD). Elevated LPI levels in combination with high TSAT levels (>80%) occurred almost exclusively in patients with MDS-RS and/or previous transfusions (Figure 1AC). Cox regression analysis for overall survival was adjusted for age at diagnosis, cumulative number of transfused units and TSAT, NTBI or LPI respectively as a time varying covariate. LPI showed a negative impact on overall survival (HR 1.97; 95%CI 0.39-9.92), independent of transfusion status (Figure 2), while NTBI and TSAT did not show relevant impact on overall survival (HR 1.04; 95% 0.91-1.20; HR 1.00; 95%CI 0.99-1.02, respectively). Conclusion: This is the first clinical outcome study which illustrates LPI as a clinically relevant assay format for identification of the toxic fraction of overt iron overload and its negative impact on overall survival. Table 1. Ferritin, Hepcidin-25, NTBI, LPI during follow-up Iron parameter Registration 1 yr follow-up 2 yrs follow-up N Median (p25-p75) N Median (p25-p75) N Median (p25-p75) Ferritin (µg/L)MDS Other: TI MDS Other: TD MDS-RS: TI MDS-RS: TD 94 51 13 26 4 274.0 (131.0 - 546.0) 188.0 (81.2 - 375.0) 408.0 (272.0 - 665.0) 271.5 (160.0 - 580.0) 947.5 (359.0 - 1333.5) 82 34 22 20 6 290.5 (149.0 - 845.0) 164.5 (78.3 - 293.0) 837.0 (550.0 - 1538.0) 257.0 (189.5 - 557.5) 1354.0 (859.0 - 2217.0) 64 28 15 11 10 346.5 (185.5 - 723.5) 204.5 (86.5 - 346.5) 642.0 (264.0 - 1970.0) 357.0 (222.0 - 597.0) 846.0 (590.0 - 1922.0) Hepcidin (nmol/L) MDS Other: TI MDS Other: TD MDS-RS: TI MDS-RS: TD 93 51 13 25 4 4.5 (2.7 - 8.4) 4.4 (2.7 - 8.3) 9.6 (4.5 - 26.3) 3.5 (1.5 - 4.9) 10.4 (7.9 - 13.5) 82 34 22 20 6 5.7 (2.7 - 12.7) 5.0 (2.3 - 8.1) 17.4 (10.2 - 23.7) 3.6 (1.7 - 5.0) 9.4 (8.8 - 14.4) 64 28 15 11 10 5.1 (2.5 - 8.9) 4.6 (2.5 - 7.1) 8.1 (2.4 - 12.8) 2.9 (1.3 - 6.1) 5.3 (2.9 - 9.3) NTBI (µmol/L) 0 RBC units <=10 RBC units >10 RBC units 91 78 12 1 0.65 (0.31 - 1.14) 0.58 (0.30 - 1.13) 0.94 (0.40 - 3.12) 0.81 (0.81 - 0.81) 76 52 12 12 0.57 (0.20 - 1.43) 0.53 (0.19 - 0.84) 0.58 (0.16 - 1.32) 2.97 (0.50 - 3.77) 60 39 14 7 0.62 (0.33 - 2.27) 0.52 (0.33 - 1.05) 1.64 (0.39 - 2.27) 3.31 (1.35 - 7.25) LPI (µmol/L) 0 RBC units <=10 RBC units >10 RBC units 91 78 12 1 0.13 (0.06 - 0.18) 0.13 (0.06 - 0.18) 0.13 (0.04 - 0.18) 0.13 (0.13 - 0.13) 76 52 12 12 0.12 (0.05 - 0.18) 0.11 (0.04 - 0.16) 0.07 (0.04 - 0.18) 0.20 (0.15 - 0.34) 60 39 14 7 0.10 (0.06 - 0.17) 0.10 (0.06 - 0.16) 0.11 (0.08 - 0.16) 0.18 (0.04 - 1.08) Figure 2. Impact of LPI on survival stratified by transfusion status (landmark analysis) Figure 2. Impact of LPI on survival stratified by transfusion status (landmark analysis) Disclosures de Witte: Novartis: Research Funding.

Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 668-668 ◽  
Author(s):  
I. Chirivella ◽  
B. Bermejo ◽  
A. Insa ◽  
A. Perez-Fidalgo ◽  
A. Magro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Negative Impact ◽  
Histological Grade ◽  
Menopausal Status ◽  
Dose Intensity ◽  
Disease Stage ◽  
Related Factors ◽  
Ct Dose ◽  
The Impact

668 Background: The relationship between chemotherapy (CT) dose intensity and patient (pt) outcome in the management of early stage breast cancer (EBC) is still controversial. Although randomised clinical trials have provided evidence that supports the delivery of full standard doses of CT on schedule, precise thresholds for CT dose-related factors and their impact on survival-related endpoints have not yet been fully defined. The objective of this project is to assess the impact of CT dose-related factors on event-free and overall survival in a large group of EBC pts treated with anthracycline-based chemotherapy. Methods: A total of 1056 EBC (stage I-II-IIIA) cases diagnosed and treated from January 1980 to December 2000 were retrospectively studied. All of them received adjuvant anthracycline non-taxanes-based CT. Consecutive charts from 793 pts that were fully completed were included in the analysis. Survival-related endpoints were analysed through Kaplan-Meier estimates, log-rank tests, and Cox proportional hazards models. Results: With a median follow-up of 10.0 years, pts exposed to either > 2 cycle-delay (delay at any cycle defined as ≥ 3 days vs. plan), or ≥ 15 day-delay across the whole CT regimen, or < 95% relative dose intensity (RDI) showed significantly worse 10-year Event-Free Survival (EFS) and Overall Survival (OS) as compared to pts with no dose delay/reduction (data shown below). Controlling for age at diagnosis, disease stage, histological grade, menopausal status and year of treatment did not modify these results. Conclusions: Based on this preliminary analysis, CT dose delays and reductions in EBC pts treated with adjuvant anthracycline-based regimens have a significantly negative impact on EFS and OS. [Table: see text] No significant financial relationships to disclose.

Mood state and melanoma outcome in the Multicenter Selective Lymphadenectomy Trial

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 9603-9603 ◽  
Author(s):  
J. R. Garreau ◽  
M. Faries ◽  
X. Ye ◽  
D. Morton
Keyword(s):  
Overall Survival ◽  
Negative Impact ◽  
Mood State ◽  
Disease Free Survival ◽  
Well Being ◽  
Mood States ◽  
Phase Iii ◽  
Selective Lymphadenectomy ◽  
The Impact ◽  
Disease Free

9603 Background: Emotional state has been linked to cancer survival, but its influence on the outcome of early melanoma is unclear. The Multicenter Selective Lymphadenectomy Trial (MSLT-I) randomized patients with clinically localized cutaneous melanoma to wide local excision (WEX) plus observation or to WEX plus sentinel lymph node biopsy (SNB). Clinical endpoints included disease-specific and disease-free survival. A substudy of this phase III trial evaluated the impact of mood state on survival, and the impact of recurrence on mood state. Methods: Patients were asked to complete a 65-question form within 6 months of enrollment (baseline) and every 12 months thereafter. This questionnaire measured 6 identifiable mood states (vigor-activity, tension-anxiety, depression, anger-hostility, fatigue-inertia, confusion-bewilderment) of the Profile of Mood States (POMS), a validated mood scale for assessing responses to therapy. Self-reported data from the questionnaires were linked to demographic and clinical variables. Results: Of 2,001 patients accrued to MSLT-I, 1,620 completed the questionnaire at baseline. The baseline distribution of POMS variables was similar in the two treatment arms (data not shown). Patients with more vigor at baseline had a significantly longer disease-free and overall survival ( Table ), even after adjusting for age, tumor thickness, site, and ulceration status (p <0.001). Among 136 patients who completed a questionnaire within 6 months after recurrence, comparison of baseline and post-recurrence responses revealed significant changes in mood state: tension, fatigue and confusion increased, whereas vigor decreased (p = 0.0004, 0.0171, 0.0089, and 0.0028, respectively). Conclusions: Vigor, a measure of energy and optimism, is directly correlated with disease-free and overall survival in early melanoma. The negative impact of recurrence on mood state suggests that SNB as a tool for preventing recurrence might also improve mood state and psychological well-being. Supported by NIH CA29605. [Table: see text] No significant financial relationships to disclose.

scholarly journals HGG-15. THE IMIPRIDONE ONC201 IN COMBINATION WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD HAS A SYNERGISTIC EFFECT IN PRECLINICAL MODELS OF PHGGS AND DMGS

2021 ◽  
Vol 23 (Supplement_1) ◽  
pp. i20-i20
Author(s):  
Daniel de la Nava ◽  
Iker Ausejo-Mauleon ◽  
Virginia Laspidea ◽  
Lucía Marrodán ◽  
Marta Zalacain ◽  
...  
Keyword(s):  
Overall Survival ◽  
Negative Impact ◽  
Pediatric Brain Tumors ◽  
Therapeutic Benefit ◽  
In Vitro Cytotoxicity ◽  
Preclinical Models ◽  
Poor Overall Survival ◽  
Significant Negative Impact

Abstract Pediatric High Grade Gliomas (pHGGs), including Diffuse Midline Gliomas (DMGs), are aggressive pediatric tumors with a poor overall survival. In the last years, ONC201 has emerged as a promising agent in the field of pediatric brain tumors. Another interesting approach is virotherapy; Delta-24-RGD, which is an oncolytic virus, has demonstrated safety and effectiveness in different preclinical models and in clinical trials. Therefore, in this work we set to evaluate whether the combination of ONC201 with Delta-24-RGD could result in an increased therapeutic benefit in pHGGs and DMGs. Given that ONC201 targets mitochondrial metabolism in a preclinical setting, we assessed potential negative interactions of the combination therapy. While ONC201 treatment resulted in decreased viral protein load (E1A and fiber), there was no significant negative impact on the viral replication (measured by hexon staining). ONC201 did not disrupt the activation of mTORC1 pathway by the adenovirus. Furthermore, Delta-24-RGD did not affect the decrease in basal oxygen consumption rate induced by ONC201. Our results suggested that ONC201 and Delta-24-RGD are not antagonistic. Evaluation of the in vitro cytotoxicity in different human pHGG (CHLA-03-AA and SF188) and DMG (TP-54 and SU-DIPG-IV) cell lines showed that the combination treatment was significantly better that either agent alone. In vivo, a single local injection of Delta-24-RGD followed by a weekly ONC201 of mice bearing CHLA-03-AA cell line orthotopically significantly increased the median overall survival (PBS: 48 days; ONC201: 54.5 days; Delta-24-RGD: 62 days; ONC201+Delta-24-RGD: 95 days (P=0.0008)) of these mice leading to 20% long-term survivors, free of disease. Currently, we are evaluating the effect of the combination in immunosuppressed and immunocompetent models of DMGs. In summary, our data indicate ONC201 in combination with Delta-24-RGD could be a potential therapeutic choice for patients affected by pHGGs and DMGs.

Do Deletions in 9p Reflect Prognosis in Adult Precursor B-Cell ALL? a Multi-Centre Study of 381 Patients

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4865-4865
Author(s):  
Hareth Nahi ◽  
Bengt Smedmyr ◽  
Helene Hallböök ◽  
Hans Hagglund
Keyword(s):  
Overall Survival ◽  
Prognostic Markers ◽  
Chromosomal Abnormalities ◽  
Negative Impact ◽  
White Cell Count ◽  
Chromosome 9 ◽  
Prognostic Impact ◽  
Multi Centre Study ◽  
Significant Negative Impact ◽  
Impact On Survival

Abstract Despite the fact that the outcome among patients with acute lymphoblastic leukaemia (ALL) has improved, the majority of adult patients relapse and die of their disease. Besides age and white cell count at diagnosis, the cytogenetic abnormalities t(9,22)/BCR-ABL and t(4,11) are important prognostic markers and are often included in the treatment stratification of patients with adult ALL. Deletions in 9p are seen in about 9% of cases of adult ALL, but their prognostic impact has been controversial. Methods: Cytogenetic data from 381 patients diagnosed with B-precursor ALL were reviewed. Chromosomal analysis was successful in 240 cases. Of these cases, 18 (8%) had abnormalities in 9p and they were compared with patients with normal karyotypes and patients with t(9;22)/BCR-ABL. Results: Patients with abnormalities of chromosome 9 showed significantly shorter overall survival compared with patients with normal karyotypes. In fact, overall survival was similar to that in the poor prognosis t(9;22)/BCR-ABL-positive group. Conclusions: The data suggest that chromosomal abnormalities involving 9p may have a significant negative impact on survival in adult B-precursor ALL.

Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2970-2970 ◽  
Author(s):  
Shaji Kumar ◽  
Angela Dispenzieri ◽  
Martha Lacy ◽  
Suzanne R. Hayman ◽  
Francis Buadi ◽  
...  
Keyword(s):  
Overall Survival ◽  
Renal Function ◽  
Renal Insufficiency ◽  
Serum Creatinine ◽  
Renal Dysfunction ◽  
Research Funding ◽  
Negative Impact ◽  
Newly Diagnosed ◽  
Number Of Patients ◽  
The Impact

Abstract Abstract 2970 Background: Over a quarter of patients (pts) with symptomatic multiple myeloma (MM) have some degree of renal insufficiency at the time of diagnosis. Multiple studies show that presence of renal failure is strong predictor of inferior overall survival in MM. With effective therapy, renal function improves in a considerable number of patients. It is not clear if the return of renal function to normal levels will improve their outcome to that expected for patients without renal dysfunction. Methods: We evaluated 1478 patients with newly diagnosed myeloma seen at Mayo Clinic within 90 days of diagnosis, between January 1999 and January 2009. We examined these patients for improvement in renal function and identified the lowest serum creatinine obtained during the disease course. The outcomes were analyzed with respect to the renal function improvements. Results: The median age at diagnosis was 64 years (range; 22–93) and 50% were male. The median estimated follow up for the entire cohort was 53 months, with 781 patients alive at the time of analysis with a median follow of 3 years. The serum creatinine was over 1.5 mg/dL at diagnosis in 333 (22.5%) pts and over 2.5 mg/dL in 148 (10%) pts. The median overall survival for the 333 patients was 37 mos (95% CI; 28, 40) compared to 56 mos (95% CI; 51, 63) for those < 1.5 mg/dL; P < 0.001. Among the 333 pts with baseline Cr > 1.5 mg/dl, any improvement in Cr was seen in 263 (79%) including an improvement of at least 0.5 mg/dL in 208 (62%) pts. Among the 263 pts with any improvement, the median time to lowest Cr was 4 months (range; 1–13). The median survival of the group of patients with Cr <= 1.5 mg/dl, over 1.5 mg/dL at diagnosis but improved to <= 1.5 mg/dL, or remained >1.5 mg/dL were 56., 40 and 27 mos respectively; P < 0.001, Figure). We then examined the impact of renal function improvement in the group of patients where the baseline Cr was >2.5 mg/dL. The median OS for the 42 (out of 148 pts with Cr > 2.5 at diagnosis) who had improved to <=1.5 mg/dL was 40 mos compared to 56 mos for those with a Cr <= 1.5 mg/dL at diagnosis and 27.4 mos for the 106 pts whose Cr did not decrease to <= 1.5 mg/dL; P < 0.001. Conclusion: The results of this study point toward improved outcome among patients with renal dysfunction in whom renal function improves. However, it shows that this improvement in renal function does not necessarily improve survival to that observed for the patients with a comparable level of serum creatinine at diagnosis. While early treatment of asymptomatic myeloma has been shown to have little impact on overall survival, a strategy of waiting for serious features of target organ damage to appear before initiation of treatment may have a negative impact on survival in some patients, especially patients with high light chain production who have a higher predilection for renal insufficiency. Disclosures: Kumar: Celgene: Consultancy, Research Funding; Millennium: Research Funding; Merck: Consultancy, Research Funding; Novartis: Research Funding; Genzyme: Consultancy, Research Funding; Cephalon: Research Funding. Off Label Use: Lenalidomide for treatment of newly diagnosed myeloma. Dispenzieri:Celgene: Honoraria, Research Funding; Binding Site: Honoraria. Lacy:Celgene: Research Funding.

scholarly journals Impact of Type of Postoperative Complications on Long-Term Survival of Gastric Cancer Patients: Results From a High-Volume Institution in China

2021 ◽  
Vol 11 ◽  
Author(s):  
Hua-Yang Pang ◽  
Lin-Yong Zhao ◽  
Hui Wang ◽  
Xiao-Long Chen ◽  
Kai Liu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Postoperative Complications ◽  
Negative Impact ◽  
Infectious Complications ◽  
Curative Gastrectomy ◽  
Term Survival ◽  
Long Term Survival ◽  
The Impact

BackgroundThis study aimed to evaluate the impact of postoperative complication and its etiology on long-term survival for gastric cancer (GC) patients with curative resection.MethodsFrom January 2009 to December 2014, a total of 1,667 GC patients who had undergone curative gastrectomy were analyzed. Patients with severe complications (SCs) (Clavien–Dindo grade III or higher complications or those causing a hospital stay of 15 days or longer) were separated into a “complication group.” Univariate and multivariate analyses were performed to reveal the relationship between postoperative complications and long-term survival. A 2:1 propensity score matching (PSM) was used to balance baseline parameters between the two groups.ResultsSCs were diagnosed in 168 (10.08%) patients, including different etiology: infectious complications (ICs) in 111 (6.66%) and non-infectious complications (NICs) in 71 (4.26%) patients. Multivariate analysis showed that presence of SCs (P=0.001) was an independent prognostic factor for overall survival, and further analysis by complication type demonstrated that the deteriorated overall survival was mainly caused by ICs (P=0.004) rather than NICs (P=0.068). After PSM, patients with SCs (p=0.002) still had a significantly decreased overall survival, and the presence of ICs (P=0.002) rather than NICs (P=0.067) showed a negative impact on long-term survival.ConclusionSerious complications, particularly of an infectious type, may have a negative impact on overall survival of GC patients. However, additional multicenter prospective studies with larger sample size are required to verify this issue.

Sign in / Sign up

Export Citation Format

Share Document